CONMED Corporation reported first‑quarter 2026 results that beat expectations, with revenue of $317.0 million—up $6.5 million from the $310.7 million consensus—and an adjusted earnings per share of $0.89, a $0.07 or 8.5% beat over the $0.82 estimate. The earnings beat was driven by disciplined cost management and a favorable product mix shift toward higher‑margin orthopedic and general‑surgery items, offsetting a 1.3% year‑over‑year decline in total sales largely attributable to the divestiture of its remaining gastro‑enterology portfolio.
The company’s gross margin expanded to 57.9% from 55.3% in Q1 2025, reflecting the mix shift away from lower‑margin GI products toward higher‑margin surgical platforms. Operating income more than doubled to $25.4 million, while operating cash flow was $13.5 million, a figure that corrects the earlier $25.4 million misstatement. The margin improvement and income growth underscore the effectiveness of CONMED’s supply‑chain optimization program and its focus on high‑growth, high‑margin segments.
CONMED raised its full‑year 2026 revenue outlook to $1.350 billion–$1.375 billion, an increase from the prior $1.345 billion–$1.375 billion range, and reaffirmed its adjusted diluted EPS guidance at $4.30–$4.45. Management also lifted its organic revenue growth outlook to 5.0%–6.5% from 4.5%–6.0%, signaling confidence in the demand for its minimally invasive surgery, smoke‑evacuation, and orthopedic soft‑tissue repair platforms.
"Our 2025 momentum continued in the first quarter as we delivered revenue and adjusted earnings ahead of our expectations," said Patrick J. Beyer, President and CEO. "We continue to concentrate our resources and investment on our higher‑growth, higher‑margin areas: minimally invasive surgery, smoke evacuation, and orthopedic soft‑tissue repair," added Beyer. Todd Garner, advisor, noted, "We are pleased to be able to raise our organic growth expectation for 2026 to 5.0% to 6.5% from our prior range of 4.5% to 6.0%." He also warned, "Our intent is to refinance with bank debt, which we expect could increase our full‑year adjusted interest expense, impacting adjusted EPS for the full year by at least $0.10."
The muted market reaction—characterized by a slight after‑hours dip—was largely driven by the unchanged full‑year EPS guidance and the anticipated increase in interest expense from the planned debt refinancing, which investors weighed against the company’s stronger operating performance and higher organic growth outlook.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.